Navigation

PrismaSol Solution

  • Generic Name: sterile hemofiltration hemodiafiltration solution
  • Brand Name: PrismaSol Solution

PrismaSol Solution (Sterile Hemofiltration Hemodiafiltration Solution) side effects drug center

  • Related Drugs
  • PrismaSol Solution Side Effects Center

    Last reviewed on RxList 11/13/2018

    PrismaSol Solution (sterile hemofiltration/hemodiafiltration solution) is an electrolyte and buffer solution used as a replacement solution in Continuous Renal Replacement Therapy (CRRT) to replace plasma volume removed by ultrafiltration and to correct electrolytes and acid-base imbalances. PrismaSol Solution may also be used in cases of drug poisoning when CRRT is used to remove filterable substances. Common side effects of PrismaSol Solution include:

    The mode of therapy, solute formulation, flow rates and length of therapy with PrismaSol Solution is selected by a doctor depending on the clinical condition of the patient as well as the patient's fluid, electrolyte, acid-base and glucose balance. PrismaSol Solution may interact with other drugs. Tell your doctor all medications and supplements you use. Tell your doctor if you are pregnant or plan to become pregnant before using PrismaSol Solution. Consult your doctor before breastfeeding.

    Our PrismaSol Solution (sterile hemofiltration/hemodiafiltration solution) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

     

    PrismaSol Solution Professional Information

    SIDE EFFECTS

    The following adverse reactions have been identified with other similar products and therefore, may occur with use of these products:

    Read the entire FDA prescribing information for PrismaSol Solution (Sterile Hemofiltration Hemodiafiltration Solution)

&Copy; PrismaSol Solution Patient Information is supplied by Cerner Multum, Inc. and PrismaSol Solution Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.